【摘要】：目的:研究分析乳腺癌患者在中醫(yī)治療腫瘤五種治療模式下用藥情況,為中西醫(yī)結(jié)合治療乳腺癌提供參考。材料與方法:選取2015年5月-6月遼寧中醫(yī)藥大學(xué)附屬醫(yī)院腫瘤科經(jīng)治的乳腺癌患者,應(yīng)用Microsoft Excel制表,進(jìn)行數(shù)據(jù)收集,包括基本情況、臨床分期、接受的西醫(yī)綜合治療情況、在2015年5-6月期間在遼寧中醫(yī)藥大學(xué)附屬醫(yī)院腫瘤科的經(jīng)治情況,根據(jù)西醫(yī)綜合治療情況判斷所處中醫(yī)治療階段(防護(hù)、鞏固、加載、維持和單純中醫(yī)治療階段),并加以統(tǒng)計(jì)分析,總結(jié)中醫(yī)治療腫瘤五種治療模式在乳腺癌患者中的應(yīng)用情況。結(jié)果:所有患者中處于中醫(yī)防護(hù)和鞏固治療階段者最多,其次為中醫(yī)加載治療階段,處于中維持和單純中醫(yī)治療階段者最少。半數(shù)以上患者處于早期(手術(shù)后無瘤),處于中期(癌灶=1處)和晚期(癌灶≥2處)者次之,處于終末期(臨終前)患者最少。早期患者均處于防護(hù)和鞏固治療階段,中期患者多處于加載治療階段,晚期患者處于維持和加載階段者最多,終末期患者均處于單純中醫(yī)治療階段。處于防護(hù)階段患者多為以防護(hù)內(nèi)分泌治療者,處于加載階段患者均為內(nèi)分泌加載,內(nèi)分泌治療患者辨證湯藥多以柴胡龍骨牡蠣湯為主方,隨證加減。結(jié)論:中醫(yī)治療腫瘤五種治療模式可聯(lián)合西醫(yī)乳腺癌綜合治療全程,值得臨床進(jìn)一步推廣應(yīng)用。
[Abstract]:Objective: to study and analyze the drug usage of breast cancer patients under five kinds of treatment modes of traditional Chinese medicine (TCM) for tumor treatment, and to provide reference for the treatment of breast cancer by integrating traditional Chinese and western medicine. Materials and methods: patients with breast cancer treated in oncology department of affiliated hospital of Liaoning University of traditional Chinese Medicine from May to June 2015 were selected and tabulated with Microsoft Excel to collect data, including basic situation, clinical stage, and comprehensive treatment of western medicine. From May to June 2015, the department of oncology in the affiliated hospital of Liaoning University of traditional Chinese Medicine (Liaoning University of traditional Chinese Medicine) judged the stage of TCM treatment (protection, consolidation, loading) according to the situation of comprehensive western medicine treatment. To summarize the application of five kinds of TCM treatment modes in breast cancer patients. Results: most of the patients were in the stage of protection and consolidation of TCM, followed by the stage of loading treatment of TCM, and the least of them were in the stage of middle maintenance and simple treatment of TCM. More than half of the patients were in the early stage (no tumor after operation), the middle stage (1 cancer focus) and the late stage (鈮，

本文編號(hào)：2185783